Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Local budding biologists explore the past, present and future during GSK Science in the Summer™ in partnership with the Franklin Institute
Free summer STEM enrichment program allows students to take on the role of biologists
-
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Learn about our first quarter 2022 results
-
US Food and Drug Administration accepts New Drug Application for daprodustat
Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme
-
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
GSK and Sierra Oncology, Inc announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology
-
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
This research was published in the Infectious Diseases Society of America’s Open Forum Infectious Diseases.
-
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
According to UNAIDS, approximately 1.7 million children globally were living with HIV in 2020.
-
ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
This approval marks the first time a long-acting HIV treatment is available for the adolescent population.
-
US Food and Drug Administration revises Emergency Use Authorization for Sotrovimab due to Omicron BA.2 subvariant
The US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab
-
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment.
-
GSK to demonstrate its commitment to improving outcomes for patients with gynecologic cancer at the 2022 SGO Annual Meeting
The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022.
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
A vaccine manufactured in plants and developed in Canada
-
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials
-
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER; Total EPS 87.6p -24% AER, -13% CER and Adjusted EPS of 113.2p -2% AER, +9% CER
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER.
-
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
ViiV Healthcare to present new long-term findings at CROI 2022
-
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement
Gilead will make an upfront payment of $1.25 billion to ViiV Healthcare in the first quarter of 2022
-
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.
-
FDA approves Nucala (mepolizumab) 40 mg prefilled syringe for children with severe eosinophilic asthma
This approval allows for at-home administration in patients 6-11 years old with severe eosinophilic asthma.
-
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
The pandemic continues to negatively impact routine immunizations in the United States
-
Tony Wood appointed Chief Scientific Officer designate, GSK
Tony Wood appointed Chief Scientific Officer designate, GSK
-
Update - GSK Consumer Healthcare
GlaxoSmithKline (GSK) plc today confirms it has received three unsolicited, conditional and non-binding proposals from Unilever plc
